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ABSTRACT
Behavioral and Neurobiological Evidence of Epigenetic Transmission in the Neonatal
Quinpirole Rodent Model of Schizophrenia
by
W. Drew Gill
Quinpirole is a dopamine D2 receptor agonist that if administered to rats from postnatal
day (P)1-21 results in increased dopamine D2 receptor sensitivity throughout the
animal’s lifetime. This increase in receptor sensitivity is consistent with schizophrenia.
This model has additional consistencies with human schizophrenia, including
sensorimotor gating deficits, enhanced behavioral and neurobiological responses to
nicotine, and protein alterations consistent with the disorder. In this study, a second
generation of the neonatal quinpirole (NQ) rodent model was created to investigate if
long term changes caused by NQ treatment would be passed to offspring. NQ treated
rats were mated and their offspring left untreated. To investigate if dopamine D2
receptor hypersensitivity was transmitted from the first to the second generation of the
model, yawning behavior was assayed after acute quinpirole treatment. Prepulse
inhibition (PPI) is a test of sensorimotor gating, and PPI testing was performed on
adolescent second generation rats. Behavioral sensitization and conditioned place
preference to nicotine (0.5 mg/kg and 0.6 mg/kg respectively) were examined in
adolescence in both generations of the model. Several neurobiological assays were
performed in both nicotine naïve and animals sensitized to nicotine (0.5 mg/kg) in order
to investigate consistencies with the NQ model, which has shown enhanced responses
to nicotine. These include enzyme linked immunosorbent assays (ELISAs) for brain-
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derived neurotrophic factor (BDNF) and cAMP response element-binding protein
(CREB), as well as quantitative PCR (qPCR) to quantify messenger RNA (mRNA) of
regulator of G-protein signaling 9 (rgs9). Results indicated that second generation rats
of NQ-treated rats demonstrated increased yawning behavior in response to acute
quinpirole treatment. PPI deficits and enhanced behavioral responses to nicotine were
also observed. Increased BDNF expression was observed in the nucleus accumbens
following nicotine sensitization, consistent with past work in first generation NQ-treated
rats. CREB expression was also increased in both generations of the model, an effect
linked to alterations in PPI and other schizophrenia-like symptomology. Rgs9
expression was generally unaltered in either generation of the model. This study
provides basis for utilization of a second generation of the NQ model to study epigenetic
influences in schizophrenia and drug abuse vulnerability.
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CHAPTER 1
INTRODUCTION
Schizophrenia is a neurological disorder that affects approximately 1% of the
population (Kahn et al. 2015). The economic burden of schizophrenia in the United
States was estimated to be greater than $155 billion in 2013 (Cloutier et al. 2016). In
addition to great economic financial strain, schizophrenia also poses serious decreases
to quality of life and lifespan of those affected. Patients diagnosed with schizophrenia
experience an average lifespan which is 12-15 years shorter than the general
population, due primarily to risk factors such as increased rate of smoking and obesity,
likely caused by decreased exercise and poor diet (Saha et al. 2007). A heightened rate
of suicide is exhibited in the population of patients diagnosed with schizophrenia, with
the lifetime suicide risk rate estimated to be at 5% (Hor and Taylor 2010). These factors
are largely influenced by the challenging nature of the treatment of schizophrenia, with
approximately 30% of patients exhibiting treatment resistance (Meltzer 1997). The
primary etiology is still largely unknown, which presents issues in identifying promising
new treatment targets. Though many advancements in schizophrenia treatment have
occurred over the past few decades, furthering understanding of the disease and
exploration of additional treatment possibilities are necessary to improve the current
landscape of schizophrenia.
Symptoms of Schizophrenia
Positive Symptoms
Schizophrenia is characterized by a multitude of symptoms, which typically begin
to present in late adolescence (Hafner et al. 1994).These symptoms are typically
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grouped into 3 categories: positive symptoms, negative symptoms, and cognitive
symptoms. Positive symptoms describe experiences that those with schizophrenia have
that do not occur in the healthy individuals. These symptoms are generally associated
with a deviation in experience from reality. Positive symptoms include hallucinations,
which can manifest in any of the sensory systems, as well as delusions (Picchioni and
Murray 2007). These symptoms present challenges to preclinical schizophrenia
researchers, as they are difficult (and potentially impossible) to detect and measure in
animal models of schizophrenia which present symptomology from the other symptom
categories. Therefore, it is difficult to assess whether novel treatments will alleviate
positive symptoms until much later in the drug development process.
Negative Symptoms
Negative symptoms describe symptoms that are deficits in healthy behavior and
response to stimuli. These symptoms include anhedonia, avolition, flattened affect,
social withdrawal, and speech deficits (Foussias et al. 2015; Sarkar 2015). Unlike many
positive symptoms, negative symptoms can be studied in animal models. Anhedonia
has been demonstrated in animal models of schizophrenia utilizing sucrose preference
(Turgeon and Hoge 2003; Baird et al. 2008). In these studies, when given free access
to either a sucrose solution or water, the animals modelling schizophrenia showed
decreased intake of sucrose solution compared to control animals, indicating that they
experience decreased rewarding effect from the sucrose solution. Avolition has been
studied in rodent models of schizophrenia using operant conditioning paradigms (Drew
et al. 2007; Simpson et al. 2011). In these studies, rodents demonstrated decreased
motivation to obtain reward via an operant conditioning paradigm requiring the rodents
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to press a lever to receive reward. While deficits to speech cannot be evaluated in
rodents as they lack use of discernable language, social deficits have been
demonstrated via examination of ultrasonic vocalizations and grooming behaviors in
rodent models of schizophrenia (Millan et al. 2014). Although the study of negative
symptoms in preclinical models is viable and has produced heightened understanding of
schizophrenia, current treatments are much less effective at treating negative symptoms
compared to positive symptoms (Tandon et al. 2008a; Foussias et al. 2015).
Cognitive Symptoms
Cognitive symptoms of schizophrenia describe symptoms that include deficits to
healthy cognitive function. Cognitive deficits are among the first symptoms to develop in
an individual diagnosed with schizophrenia (Mesholam-Gately et al. 2009). Cognitive
symptoms of schizophrenia include deficits to memory, attention, learning, and
executive function (Tan 2009). Both working memory (Karlsgodt et al. 2007) and
declarative memory (Karlsgodt et al. 2007) have been shown to be affected. These
cognitive symptoms of schizophrenia have been extensively demonstrated by various
models of the disease (Thacker et al. 2006; Miyamoto and Nitta 2014).
Prepulse inhibition (PPI) is a task that has been used to study cognitive
performance in both individuals diagnosed with schizophrenia as well as rodent models
of the disease (Light and Swerdlow 2014). PPI is a task that measures sensorimotor
gating. Sensorimotor gating is the ability to use sensory stimuli to inhibit a motor
response (Powell et al. 2012). Patients diagnosed with schizophrenia consistently
demonstrate PPI deficits (Braff et al. 2001). However, PPI deficits are not limited to
schizophrenia. Many other neurological conditions exhibit PPI deficits including
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obsessive compulsive disorder, Tourette syndrome, and Huntington’s disease
(Swerdlow et al. 1995; Neal R. Swerdlow et al. 2001; Ahmari et al. 2012). PPI
performance is affected by many brain regions and genes, but the PPI deficit phenotype
appears to be heritable (N. R. Swerdlow et al. 2001; Greenwood et al. 2011). PPI has
been shown to be critically useful in the screening process for models of schizophrenia.
PPI has been demonstrated to correlate with various cognitive processes including
working memory (Greenwood et al. 2013) and executive function (Bitsios et al. 2006;
Swerdlow, Light, et al. 2006). Examination of PPI allows for the study of effectiveness of
schizophrenia treatment. Atypical antipsychotics elevate PPI performance in
schizophrenia patients as well as animal models (Swerdlow, Talledo, et al. 2006). Since
PPI deficits have been demonstrated to be a hallmark of the disease (Light and
Swerdlow 2014), their omission from any model brings validity to question of any such
model.
Drug Abuse Vulnerability
A consistency of people diagnosed with schizophrenia is an increased rate of
drug abuse, particularly with nicotine, alcohol, and cannabis (Barbee et al. 1989; Soyka
et al. 1993; Salokangas et al. 2006; Featherstone and Siegel 2015). Focusing on
nicotine, individuals diagnosed with schizophrenia are four times more likely to smoke
tobacco, in which nicotine is the psychoactive ingredient in tobacco, than the healthy
population (Featherstone and Siegel 2015). Additionally, individuals diagnosed with
schizophrenia are more likely to be heavy smokers as well, which is defined as more
than one and a half packs of cigarettes per day (Salokangas et al. 2006). While the
cause of this increased rate in nicotine use is unknown, it has been suggested that
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nicotine may provide relief from negative and cognitive symptoms associated with
schizophrenia (LeDuc and Mittleman 1995). However, smoking produces several issues
for individuals with schizophrenia. Smoking has been demonstrated to reduce blood
levels of some antipsychotics, which play an important role in mitigating cognitive and
positive symptoms of the disease (Jann et al. 1986; Carrillo et al. 2003). Smoking also
introduces increased risk of lung and other cancers, respiratory illnesses, and
cardiovascular diseases (Bonnie et al. 2015). Therefore, while nicotine may provide
some therapeutic effects, the detriments to quality of life for individuals with
schizophrenia necessitate research to alternatives and therapies that alleviate the rate
of addiction in the affected population.
Dopamine Hypothesis of Schizophrenia
The exact cause of schizophrenia is still unknown. In fact, it is more likely that
there is no specific singular cause for the symptomology of schizophrenia, and rather
there are several contributing factors (Tandon et al. 2008b). However, a major
underlying mechanism of the schizophrenia pathology is an increase in dopamine
signaling and dysregulation, often referred to as the “Dopamine Hypothesis of
Schizophrenia”. This hypothesis states that the behavioral symptoms of schizophrenia
are caused by or related to dysfunction and/or hyperactivity in the dopamine systems in
the brain (Howes and Kapur 2009). Some of the initial evidence for this theory was that
antipsychotics that have proven effective at treating at least parts of the disease all
antagonize dopamine D2 receptors (Seeman et al. 1976). There are three dopaminergic
pathways in the brain which may explain and contribute to schizophrenia pathology. The
mesolimbic pathway, or reward pathway, is the ventral tegmental area (VTA) to the

14

nucleus accumbens pathway. Dopamine alterations in this pathway may contribute to
positive symptoms (Davis et al. 1991), increase incidence of drug addiction such as
nicotine abuse in schizophrenia (Brown et al. 2012; Perna and Brown 2013; Lucatch et
al. 2018), and also contribute to negative symptoms such as avolition (Salamone et al.
2007). The mesocortical pathway is the VTA to the prefrontal cortex pathway and is
important in mediating cognitive processes and decision making, which are both
deficient in schizophrenia (Floresco and Magyar 2006). The mesocortical pathway is
also implicated in negative symptoms (Toda and Abi-Dargham 2007), due to its
relationship to emotional reactivity. The nigrostriatal pathway is the pathway from the
substantia nigra to the dorsal striatum. Dopamine signaling in the nigrostriatal pathway
affects motor function as well as cognition (Graybiel 2008), and alterations to this
pathway could explain learning deficits which are manifested in schizophrenia (Bach et
al. 2008). The nigrostriatal pathway has also been implicated in the neurobiology of
addiction (Wise 2009).
Dopamine D2 receptor antagonism is a focus of disease treatment (Abi-Dargham
et al. 2000). It has been demonstrated that there are proportionately fewer unbound
dopamine D2 receptors in individuals diagnosed with schizophrenia than the healthy
population, indicating greater signaling through the dopamine D2 receptor in
schizophrenia (Abi-Dargham et al. 2000). Dopamine D2 receptors have high-affinity and
low-affinity states (Sibley et al. 1982). This increased binding of D2 receptors is
indicative of an increased number of D2 receptors in the high-affinity state, or increased
D2 receptor activity in this state, and this phenomenon has been demonstrated to occur
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in patients diagnosed with schizophrenia as well as all relevant animal models (Seeman
2011).
Alternative Schizophrenia Hypotheses
While altered dopamine signaling is a hallmark of schizophrenia, there is
disruption in other neurotransmitter systems in schizophrenia. For example, serotonin
has been suggested to play a role in schizophrenia, affecting negative symptomology
(Bleich et al. 1988). Additionally, antipsychotic medications in the atypical class also act
on serotonin signaling, suggesting that serotonin dysfunction may play a role in the
disease (Schmid et al. 2014). Post-mortem studies have also implicated serotonin
receptors in schizophrenia pathology (Ngan et al. 2000).
Another neurotransmitter system affected in schizophrenia is glutamate. Many
studies have shown hypoactive glutamatergic signaling contributes to schizophrenia’s
symptomology, and does so primarily through N-methyl D-aspartate (NMDA) receptor
dysregulation (Stone et al. 2007). This hypothesis was in-part developed due to NMDA
receptor antagonists resulting in similar symptoms to schizophrenia (Javitt 1987). This
has also led to the development of schizophrenia models based on NMDA receptor
antagonism (Olney et al. 1999; Lacroix et al. 2000). Though treatments targeting the
glutamate system have previously been in development, no currently utilized treatments
have been effective as NMDA receptor agonists. While it may seem that these
hypotheses are competing, it is likely dysregulation of all three neurotransmitter systems
contributes to schizophrenia symptomology (Howes et al. 2015). Therefore, while this
dissertation project focuses primarily on dopaminergic contributions to schizophrenia,
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research into either hypothesis is valuable to the continued understanding of the
disease.
Epigenetic Transmission of Gene Regulation
Evidence of Epigenetic Contribution to Schizophrenia
Schizophrenia etiology is likely the combination of various genetic,
environmental, and epigenetic factors, but the specifics of these factors are largely
disputed. A key finding to support a mix of genetic and epigenetic factors is that
monozygotic twins have a 41-65% concordance rate of schizophrenia compared to a 028% rate in dizygotic twins (Cardno and Gottesman 2000). Risk of the development of
schizophrenia when just one parent has the disorder is around 13%, rising to 46% if
both parents are diagnosed (Bromet et al. 2003). More than 700 genes have been
researched as candidates for contributing to schizophrenia’s etiology (Allen et al. 2008).
Some of the most studied genes in relation to schizophrenia include brain-derived
neurotrophic factor (BDNF), disrupted in schizophrenia 1 (DISC1), and dopamine
receptor D2 (Farrell et al. 2015). Though heritability evidence as well as genetic studies
demonstrate the importance of genetic variation in the etiology of schizophrenia, the
lack of concordance between monozygotic twins suggest that the epigenome must also
play an important role in the etiology of the disease. It is also important to note that
heritability rates are not linked strictly to genetic variations, and that epigenetics also
likely play an important role in heritability. In order to discuss how parts of the
epigenome could be transmitted across generations, it is important to discuss the
mechanisms affecting the epigenome and how these mechanisms ultimately conserved
across generations.
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Molecular Epigenetic Mechanisms
Epigenetics refers to molecular mechanisms which affect genetic expression
without change to DNA sequence (Dupont et al. 2009). Many epigenetic mechanisms
have been discovered, but chromatin remodeling is likely the most studied of these
mechanisms. Chromatin is comprised of a complex of DNA and histones. Histones are
proteins which form complexes to aid in compacting DNA (Strahl and Allis 2000). A
useful, albeit imperfect, analogy to visualize histone function is that histone complexes
act as a “spool”, with DNA acting as the “thread”. The tighter DNA is wound around the
histone “spool”, the lower the transcription of genetic material interacting with the
histone (Strahl and Allis 2000; Kramer 2013). Several molecular processes can lead to
changes in the associations between DNA and histones, including DNA methylations (at
CpG sites or not) and histone methylation, acetylation, or phosphorylation (Handy et al.
2011). Of these processes, the most studied pertaining to epigenetic inheritance is DNA
methylation at CpG sites. This specific methylation event is most commonly correlated
with downregulation of a gene via condensing of chromatin structure (i.e tightening of
the DNA “thread” around the histone “spool”) (Strahl and Allis 2000).
Epigenetic Transmission Across Generations
The degree to which many epigenetic mechanisms controlling gene expression
may be inherited by a future generation of offspring depends on the type of epigenetic
mechanism and also on which parental sex is the contributor of a given epigenetic
modifier. With regards to sex, maternal womb environment has large implication for
epigenetic manipulation. A study of Dutch families following a famine found that adult
offspring of parents who suffered through famine conditions experienced long lasting
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metabolic issues, more attributed to maternal womb environment than epigenetically
altered gamete genetic material (Lumey et al. 2007; Horsthemke 2018). However,
epigenetic modifications to genetic material of germline cells also has implications for
epigenetic transmission of gene regulation. Epigenome reprogramming is vitally
important in the formation of germline cells. Epigenetic modifications are major
contributors to cellular differentiation, and therefore are removed in order for germline
cells to exhibit pluripotency (Tang et al. 2015). This is an effect which is seen in
gametes of both parental sexes, but appears to be more dramatically exhibited in
paternal germ-cells (Guo et al. 2014). Importantly, this reprogramming of gene
methylation does not appear to affect the entire epigenome, as it appears some genegroups linked to metabolic disorders such as diabetes and obesity, and neurological
disorders such as schizophrenia are protected from this reprogramming event (Wei et
al. 2014; Tang et al. 2015). Therefore, risk factors of disorders which are linked to
epigenetic mechanisms such as DNA methylation have potential to be transmitted
across generations.
Schizophrenia Treatment
There are two classes of antipsychotics that are directed towards treatment of
schizophrenia. Second-generation antipsychotics, also called atypical antipsychotics,
are the most commonly prescribed medications for schizophrenia. Atypical
antipsychotics act primarily through dopamine D2 receptor antagonism, although they
also bind serotonin receptor 5-HT2A receptors, along with a number of other
pharmacological targets (Seeman 2002). While proven to be effective to alleviate
positive symptoms of schizophrenia, atypical antipsychotics do little to improve negative
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and cognitive symptoms, although they were designed to do so (Tandon et al. 2008a;
Foussias et al. 2015). Of atypical psychotics, clozapine has proven the most commonly
effective (Leucht et al. 2013). However, approximately 40-70% of individuals diagnosed
with schizophrenia are resistant to treatment with clozapine (Taylor and DuncanMcConnell 2000).
Additionally, significant side-effects are a concern with atypical antipsychotics.
Weight gain and associated metabolic conditions have been demonstrated to be a
major side-effect of several antipsychotics (Allison et al. 1999; De Hert et al. 2012).
Weight gain combined with inability to treat negative symptoms likely explain relatively
low adherence to atypical antipsychotic prescriptions by patients diagnosed with
schizophrenia. One study of 1493 patients diagnosed with schizophrenia across the US
found that the 18-month adherence rate to atypical antipsychotics to be 26% (Leucht et
al. 2013). Reasons given for discontinuation of use of medication largely revolved
around both ineffectiveness of the medication to treat symptoms and intolerable sideeffects. Significant side effects and low adherence rates to the most effective current
treatments of schizophrenia highlight the need for novel treatment options and better
understanding of the disease. To accomplish this, preclinical research utilizing effective
modeling of schizophrenia is necessary.
Preclinical Models of Schizophrenia
Accurately modelling a complex neurological disorder such as schizophrenia
presents many challenges. As the disease is recognized and diagnosed primarily based
on behavior, cell lines are generally ineffective at modelling most aspects of
schizophrenia. Another challenge is that the positive symptoms of schizophrenia, such
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as hallucinations and delusions, cannot be studied in animal models. Consequently,
models can only be validated based on negative and cognitive symptoms of the
disease. More than 20 distinct models of schizophrenia have been developed and
utilized to study behavioral, biochemical, genetic, and epigenetic aspects of
schizophrenia (Carpenter and Koenig 2008). These models can be assigned to one of
four categories: genetic models, lesion models, pharmacological models, and
neurodevelopment models. Each of these model types, as well as individual models
pertaining to each type, provide opportunities for studying particular aspects of
schizophrenia, but not all models are suitable for studying every component of the
disease.
Several genes have been suggested to play a role in schizophrenia etiology,
most of which genes play a role in glutamatergic or dopamine systems, synaptogenesis,
and neuronal plasticity (Harrison and Weinberger 2005). Mice with disrupted in
schizophrenia 1 (DISC-1) knockout are one of the most common genetic-manipulation
based models of schizophrenia (Jones et al. 2011). Notably, DISC-1 models altered
ventricle size as well as PPI deficits which are reversed by antipsychotics (Clapcote et
al. 2007; Jaaro-Peled et al. 2010). While DISC-1 knockouts and other genetic models
can accurately reflect schizophrenia phenotype, they require genetic manipulations that
could potentially be the consequence of epigenetic regulation in human schizophrenia.
Therefore, the potential for study of epigenetic mechanisms in genetic manipulation
models is limited.
Lesion models of schizophrenia involve the use of a brain lesion to produce
schizophrenia-like phenotype. One commonly used lesion-induced model of
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schizophrenia is the neonatal ventral hippocampal lesion model. This model is induced
by acute bilateral injection of ibotenic acid, an endotoxin, into the ventral hippocampus
of rats under anesthesia on post-natal day 7 (P7) (Lipska and Weinberger 1993). This
treatment results in developmental changes in the rat, with key symptoms including
enhanced dopamine D2 receptor sensitivity and impaired sensorimotor gaiting
manifesting by P56 (Lipska and Weinberger 1993; Wan and Corbett 1997; Le Pen et al.
2000). This developmental progression closely models human schizophrenia, as human
schizophrenia tends to present between the ages of 16-25 years, with P60 in rats
generally being regarded as similar to a young adult (Sham et al. 1994). Relevant to this
study, epigenetic alterations have been studied in this model and were demonstrated to
play a large role in the induction of schizophrenia-like phenotype (Sandner et al. 2011).
However, a critique of this model as well as other lesion-induced models of
schizophrenia is that cell death is not present in schizophrenia (Harrison 1999; Harrison
and Eastwood 2001).
Pharmacological models of schizophrenia rely on drug treatment, typically in
adult rats, to induce a schizophrenia-like phenotype. Most commonly, phencyclidine
(PCP) administration to rats either acutely or chronically to model symptoms seen in
schizophrenia (Jones et al. 2011). PCP is an NMDA antagonist which elicits a psychosis
response including hallucinations, paranoia, and catatonia (Bey and Patel 2007). It is for
these schizophrenia-like symptoms following the use of this drug in otherwise healthy
individuals that PCP was selected as a pharmacological agent for schizophrenia studies
(Cohen et al. 1962). PPI deficits have been demonstrated in PCP-induced models, but
these deficits diminish even in chronic models a soon following the cessation of PCP
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treatment (Martinez et al. 1999). Pharmacological models do provide opportunity to
study epigenetic related changes in expression levels of genes as well as investigate
epigenetic mechanisms. However, since pharmacological models involve treatment
typically being administered in adult rats, and effects in these models are often shortlived following drug treatment, the neurodevelopmental aspect of schizophrenia and its
epigenetic components cannot be studied in models which do not incorporate a
developmental period. This is important for the study of epigenetic mechanisms and
their transmission, as schizophrenia is currently thought of as a neurodevelopmental
disorder (Jones et al. 2011).
Neurodevelopmental models of schizophrenia are defined here as models which
utilize gestational or neonatal treatments in order to produce schizophrenia-like
phenotypes as a young rat ages. Neurodevelopmental models attempt to model not
only the symptoms of the disease, but also the development of the disease. Gestational
treatment with the microbial anti-inflammatory molecule protein (MAM) produces longlasting schizophrenia-like symptoms in offspring of treated rats via DNA methylation
(Matsumoto and Higa 1966; Lodge and Grace 2009; Jones et al. 2011). Given the
developmental aspect, as well as long-lasting effects, neurodevelopmental models
provide an opportunity to study epigenetics of schizophrenia as it relates to etiology,
development, behavior, and pathology in a convergent way that many other model
types do not.
Neonatal Quinpirole Model
The neonatal quinpirole (NQ) model is the neurodevelopmental model of
schizophrenia utilized in this study. This model focuses on alteration to the dopamine
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signaling system observed in human schizophrenia, primarily hypersensitive dopamine
D2 receptors (Brown et al. 2012). Quinpirole is a selective dopamine D2/D3 receptor
agonist which when administered to rats neonatally from P1 to P21 produces lifelong
increase in the sensitivity of the dopamine D2 receptor (Kostrzewa et al. 2016). As
previously mentioned, hypersensitivity of the dopamine D2 receptor is a biomolecular
hallmark of the disorder and has been suggested to be the convergent point for many
disrupted pathways observed in human schizophrenia (Seeman 2002). Behavioral
validating findings within this model include cognitive impairments, PPI deficits,
increased yawning in response to acute quinpirole in adulthood, and enhanced nicotine
sensitization and conditioned place preference compared to neonatal saline-treated
controls administered nicotine (Thacker et al. 2006; Brown et al. 2012; Maple et al.
2015; Peterson et al. 2017; Brown et al. 2018). Decreases in hippocampal nerve growth
factor (NGF), choline acetyltransferase (ChAT), as well as a decrease in regulator of gprotein signaling 9 (rgs9) expression in dopamine terminal areas have all been
observed (Brown et al. 2002; Maple et al. 2007; Brown et al. 2008), consistent with
human schizophrenia (Bird et al. 1977; Perez-Polo et al. 1978; Seeman et al. 2007).
These validations, as well as the neurodevelopmental nature of the model, provide the
basis for utilizing this model to study epigenetic aspects, mechanisms, and transmission
of schizophrenia as it pertains to dopamine D2 receptor hypersensitivity.
This model has been used to extensively study nicotine abuse and schizophrenia
comorbidity. NQ treated rats exhibit a significantly increased response to nicotine in
behavioral sensitization and conditioned place preference protocols (Brown et al. 2012;
Perna and Brown 2013; Peterson et al. 2017; Brown et al. 2018). Upregulation of
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neurotrophic factors BDNF and glial cell-derived neurotrophic factor (GDNF) following
nicotine administration in these rats may partially explain the elevated response to
nicotine in NQ rats (Perna and Brown 2013; Peterson et al. 2017; Brown et al. 2018).
BDNF is a ubiquitously expressed protein which mediates neuroplasticity and has also
been implicated in addiction development (Kowiański et al. 2018). GDNF is expressed
primarily in areas of dopamine signaling, and is important in promoting dopamine
neuron survival as well as neuroplasticity (Granholm et al. 2000; Lindholm et al. 2016).
GDNF is also thought to mediate addiction (Kotyuk et al. 2016). Given this
demonstrated enhanced response to nicotine in the NQ model, this model provides an
opportunity to study how the epigenetic transmission of effects caused by dopamine D2
receptor hypersensitivity affects the potential for nicotine abuse in schizophrenia.
Study Purpose and Hypotheses
The purpose of this research project is to investigate the epigenetic transmission
of dopamine hypersensitivity and associated schizophrenia-like effects utilizing the NQ
rodent model of schizophrenia. Investigating if hypersensitivity at dopamine D2
receptors can be transmitted to offspring and how it occurs could lead to a better
understanding of the elusive etiology of schizophrenia. Additionally, understanding this
phenomenon could lead to identifications of novel treatment targets in schizophrenia, as
well as highlight the function of dopamine hyperfunction as it pertains to both
schizophrenia and drug abuse (specifically nicotine).To do this, rats neonatally treated
with quinpirole (F0 rats) were mated, and the offspring, which were not treated
neonatally, (F1 rats) were investigated for dopamine D2 receptor hypersensitivity. To
investigate if both parents being treated neonatally was necessary for transmission of
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dopamine D2 receptor hypersensitivity or if one parental-sex contributed more in
epigenetic transmission, three different crosses were used to produce a second
generation of the NQ rodent model of schizophrenia. One mating pair consisted of both
parent rats being treated neonatally with quinpirole. The other two mating pairs
consisted of one parent being treated neonatally with quinpirole, and the parent of the
opposite sex being treated neonatally with saline.
To verify if dopamine D2 receptor hypersensitivity is passed along to F1 rats, a
yawn test was performed on both generations of the NQ rodent model. The yawn test is
a behavioral measure of dopamine D2 receptor sensitivity in which rats are injected with
quinpirole, a dopamine D2 receptor agonist, and the number of times the rat yawns
following this injection is counted for 1 hour. Yawning has been demonstrated to be D2like receptor mediated (Cooper et al. 1989), and was shown to be elevated in neonatally
quinpirole treated rats (Kostrzewa et al. 2016). Therefore, we hypothesized that
yawning would be elevated following dopamine D2 receptor agonist injection in the
neonatally untreated F1 rats with at least one neonatally treated quinpirole parent. PPI
testing was used to measure sensorimotor gating in F0 and F1 rats. We hypothesized
that like F0 neonatally treated quinpirole rats in previous studies (Maple et al. 2015), F1
with at least one neonatally treated quinpirole parent would exhibit PPI deficits
compared to neonatal saline-treated controls.
We also investigated the effects nicotine would have on F1 rats. We
hypothesized that F1 rats with at least one neonatally treated quinpirole parent would
exhibit an enhanced response to nicotine via condition placed preference (CPP) and
locomotor activity following a behavioral sensitization paradigm, as well as demonstrate
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elevated BDNF expression following administration of nicotine. All of these nicotinerelated effects have been demonstrated to be enhanced in F0 neonatally quinpirole
treated rats (Brown et al. 2012; Peterson et al. 2017; Brown et al. 2018).
Potential mechanisms for hypersensitivity of dopamine D2 receptors in F1 rats
were also investigated. Regulator of g-protein signaling 9 (rgs9) expression was
investigated using qPCR. Rgs9-2, the splice isoform of rgs9 which is found in the brain,
is a protein which binds to dopamine D2 receptors and prevents the receptor from
achieving its high affinity state (Cabrera-Vera et al. 2004). Rgs9 has been shown to be
downregulated in human schizophrenia (Seeman et al. 2007) and in the NQ rodent
model (Maple et al. 2007). Therefore, we hypothesized that rgs9 RNA expression would
be decreased in F1 rats with at least one neonatally treated quinpirole parent.
CREB protein expression was also investigated as a potential contributor to
downstream effects of increased dopamine signaling. CREB primarily functions as a
transcription factor, and is activated by phosphorylation by protein kinase A (PKA) as
well as other kinases (Pláteník et al. 2005; Alberini 2009). CREB phosphorylation is
linked to dopamine D2 receptor signaling (Yan et al. 1999). Alterations to CREB activity
in the nucleus accumbens have been linked to PPI deficits (Culm et al. 2004) as well as
blunted emotional response to aversive stimuli (Carlezon et al. 2005), both of which
exist in schizophrenia. Therefore, an increase in CREB expression in the nucleus
accumbens could be a downstream mechanism of epigenetically transmitted effects of
dopamine D2 receptor hypersensitivity.
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CHAPTER 2
MATERIALS AND METHODS
Animals and Materials
Subjects
A total of 311 animals were utilized in this study. All parts of this study were
conducted using Sprague-Dawley rats. Postnatal day (P)0 indicates the day of birth of
the subject animal. Subjects were weaned from their mother on P21. After weaning,
subjects were socially housed, with 2-4 rats per cage, until the end of the experiment
they were assigned to. All animals were housed on a 12 hour light and 12 hour dark
cycle. Food and water were made available ad libitum throughout all experiments. All
procedures for this study were approved by the East Tennessee State University Animal
Care and Use Committee, which complies with the NIH Guide for the Care and Use of
Animals.
Pharmacological Materials
This study utilized two drugs for treatment of rat subjects. Quinpirole HCl, a
dopamine D2/D3 receptor agonist, and nicotine hydrogen tartarate were ordered from
Sigma-Aldrich, Inc. (St. Louis, MO, USA).
Model Generation
Neonatal Treatment of F0 Rats
F0 rats in this study refer to rats which represent the first generation of rats being
investigated. All F0 rats in this study were administered daily intraperitoneal (IP)
injections of either saline (0.9% NaCl) or quinpirole HCL (1 mg/kg mixed in saline) from
P1 to P21. F0 rats treated neonatally (N) with saline (S) are referred to in this study as
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F0 NS. F0 rats treated neonatally (N) with quinpirole (Q) are referred to as F0 NQ.
Neonatal treatment with quinpirole (NQ) produces rats with schizophrenia-like
symptoms, detailed in Chapter 1. Rats treated neonatally with saline (NS) serve as
controls. The purpose of saline injections is to control for stress of the injection.
Establishment of F1 Rats
In order to study the epigenetic transmission of schizophrenia-like symptoms
conferred via NQ treatment, a second generation (F1) of rats were created. F1 rats are
the offspring of F0 neonatally treated rats. F1 rats were not treated neonatally, but
identical to F0 rats, were weaned from the female dam on P21. Three different parental
mating-pair types were used to investigate the differences between epigenetic
transmission contribution based on sex. The mating pair consisting of FQ and MQ was
used to investigate epigenetic transmission when both parents were treated neonatally
with quinpirole. Offspring from this mating-pair type will be referred to as F1 FQxMQ
rats. The mating pair of FQ and MS was used to investigate the female parent rat’s
epigenetic contribution of transmission of schizophrenia-like symptoms. Offspring from
this mating-pair type will be referred to as F1 FQxMS rats. The mating pair of FS and
MQ was used to investigate the male parent rat’s epigenetic contribution of transmission
of schizophrenia-like symptoms. Offspring from this mating-pair type will be referred to
as F1 FSxMQ rats.
It is possible that neonatal treatment may affect parental behavior, and that
altered parental behavior could play a role in the development of a phenotype in F1 rats.
To investigate this possibility, a subset of F1 rats were cross-fostered to a maternal
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parent of the opposite neonatal treatment on P1. Table 1 serves as a reference for the
abbreviations used for all treatment groups throughout the study.
Table 1: Description of F0 and F1 Group Abbreviations
Abbreviation

Description

F0 NS

Rats treated neonatally with saline (0.9%, 1 mL/kg, IP)

F0 NQ

Rats treated neonatally with quinpirole (1 mg/kg, IP)

F1 FQxMQ

Untreated offspring of a female NQ and male NQ rat

F1 FQxMS

Untreated offspring of a female NQ and male NS rat

F1 FSxMQ

Untreated offspring of a female NS and male NQ rat

F1 FSxMS

Untreated offspring of a female NS and male NS rat

Experimental Methods
Yawn Test
To measure sensitivity of dopamine D2 receptors, F0 and F1 rats at age P60
were administered the yawn test as outlined by Kostrzewa and Brus (Kostrzewa and
Brus 1991). Rats were given an IP injection of quinpirole (0.1 mg/kg) and immediately
observed for 60 min. During this time, the number of times the rat yawned was counted.
Yawning has been demonstrated to be a dopamine D2 receptor mediated event
(Cooper et al. 1989), and increased sensitivity at the dopamine D2 receptor would
manifest in increased yawning following administration of a dopamine D2 agonist such
as quinpirole.

30

Auditory Prepulse Inhibition
The methods used for PPI testing in this was performed based on previous work
from our laboratory (Maple et al. 2015). Beginning at P44, F0 and F1 rats were
administered PPI testing sessions once daily for 3 days. The testing apparatus
consisted of an tall stainless-steel dome with hard plastic flooring (8 cm tall x 11 cm
wide x 15 cm long) mounted on top of a weight-sensing platform, all of which was
contained within a sound attenuating chamber (28 cm tall x 30 cm wide x 36 cm long).
The software utilized was Kinder Scientific Startle Monitor (Poway, CA, USA). After
being placed into the testing apparatus, a 5 min habituation period was administered, in
which only a background 70 decibels (dB) of white noise is played through a speaker
inside of the sound attenuating chamber. After habituation, rats were administered 60
total trials during the daily session. For the duration of the 60-trial session, the 70
decibels (dB) of background white noise was played. Three different trial types made up
the 60 total trials, including 20 pulse trials, 30 prepulse trials, and 10 no stimulus trials
played in a semi-random order with randomized inter-trial intervals ranging between 8
and 22 seconds (s). A pulse trial consisted of a 120 dB auditory pulse followed by a 250
ms measuring window in which the startle response of the subject was measured in
Newtons (N). A prepulse trial consisted of a prepulse, followed 100 ms later by a 120 dB
pulse and 250 ms measuring window. The 30 prepulse trials were made up of 3
different prepulse trial types of differing prepulse dB levels, including 10 of each of the
following: 73 dB prepulse trials, 76 dB prepulse trials, and 82 dB prepulse trials. A no
stimulus trial consists of a 250 ms measuring window with no preceding prepulse or
pulse. Each PPI data session including habituation period lasted for a duration of
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approximately 20 min. Data collected through the Startle Monitor software was
averaged over 3 days of testing.
Nicotine Behavioral Sensitization
At P30, female F0 and F1 rats were placed into a locomotor arena (black
plexiglass cube with open top side; 91 cm tall x 91 cm wide x 91 long) 15 min following
an IP saline injection for 5 min once daily for 3 days to habituate them to the testing
arena. Starting the following day (P33), rats were IP injected with either saline or
nicotine (0.5 mg/kg). Rats were placed into the locomotor arena 15 min later where they
remained for 10 min. During the 10 min period in the locomotor arena, the total distance
traveled by the rat was recorded as a measure of overall activity. Activity was measured
in distance (m) and was calculated as a difference in activity from Day 1 to Day 9 of
nicotine treatment. This saline or nicotine injection followed by locomotor measurement
was administered every other day over 18 days with nine total drug administrations.
Animal tracking was performed using AnyMaze behavioral scanning software (Stoelting
Co., Wood Dale, IL, USA).
Nicotine Conditioned Place Preference (CPP)
A three chambered CPP apparatus (61 cm deep x 33 cm wide x 81 cm long) was
utilized for this test. The three chambers all have identical dimensions (33 cm wide x 27
cm long) but have distinct tactile and visual contexts. The middle chamber flooring is
made of Plexiglas, with walls painted black. One of the two outside chambers flooring is
made of chicken-wire style metal and has vertical black and white stripes. The other
outside chamber flooring is made of thin metal rebar and has horizontal black and white
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stripes. The chambers are separated by removable dividers, which were removed to
allow free movement among the three chambers.
F0 and F1 rats were administered two initial preference tests on P41 and P42 to
determine initial context preference. During this initial preference test, rats were IP
injected with saline, followed by a 10 min waiting period. Rats were then placed into the
apparatus with dividers removed and allowed to freely explore the apparatus for 10 min.
Mean time spent in the vertical and horizontal-striped contexts across the two testing
days determined initial preference. Conditioning began on P43 and was conducted
every day through P50, with the dividers placed into the apparatus. Conditioning
consisted of 2 trials per day, an AM session and a PM session. During the AM session,
all subjects were IP administered saline and placed into their assigned unpaired context
for a 10 min trial. During the PM session, all rats were administered an IP injection of
saline or nicotine (0.6 mg/kg) and placed into the paired context for a 10 min trial. The
assignment of each context was selected so that the paired context for each subject
was the opposite context of their initial preference. If there was no robust initial
preference, the paired context was randomly chosen. On P51, rats were again tested
for context preference as they were on P41 and P42, termed the post-conditioning
preference test. The percent difference between the post-conditioning context
preference and the pre-conditioning context preference was used as the measure of
CPP. Animal tracking was performed using AnyMaze behavioral scanning software
(Stoelting Co., Wood Dale, IL, USA).
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Brain-derived Neurotrophic Factor Enzyme-linked Immunosorbent Assay (ELISA)
Approximately 24 hours following the final nicotine injection of the behavioral
sensitization paradigm, female rats from all five treatment groups were decapitated and
their brain tissue collected. Brains were immediately frozen in isopentane and stored at
-80°C. Nucleus accumbens tissue was dissected from each brain and stored at -80°C. A
BDNF ELISA kit was purchased from Promega, Inc. (Madison, WI). The provided
protocol for this kit was followed, as described in a previous publication from our
laboratory (Perna and Brown 2013). In brief, nucleus accumbens tissue was
homogenized in RIPA cell lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 1.0% NP-40,
0.5% Sodium deoxycholate and0.1% SDS) containing protease and phosphatase
inhibitors P5726, P8340, and P0044 (Sigma-Aldrich, St. Louis, MO) using a sonic tissue
homogenizer (Fisher Dismembrator 500). Tissue homogenates were centrifuged at
14,000g for 20 minutes and the supernatants extracted. A 96-well polystyrene plate was
then coated with monoclonal anti-BDNF antibody using a carbonate coating buffer and
concentration of antibody specified in the protocol provided by Promega. The coated
plate was incubated overnight. A BDNF standard curve was prepared using BDNF
protein isolate following dilution recommendations in the provided protocol. After
washing with the supplied wash buffer, samples and the prepared BDNF standard were
then added to the 96-well plate and incubated for 2 hours. Polyclonal BDNF antibody
was then added, followed by an additional 2-hour incubation. Anti-IgY horseradish
peroxidase conjugate was then added to the 96-well plate. TMB one solution was then
added to the 96 wells and incubated for 10 minutes, followed by the addition of 1N
hydrochloric acid to stop the reaction and allow for measurement to occur at 450 nm. To
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quantify protein amount, optical density was measured using a Bio-Tek ELx 800
microplate reader (Winooski, VT).
Rgs9 Quantitative Polymerase Chain Reaction (qPCR)
F0 and F1 rats were decapitated at P60. A subset of these rats received 6 days
of once daily nicotine injections (0.5 mg/kg, IP), with the final injection being 24 hours
prior to decapitation at P60. Brains frozen in isopentane and stored at -80°C. Nucleus
accumbens tissue was dissected from each brain and again stored at -80°C. Brains
were then homogenized by hand in TRIzol (ThermoFisher, Waltham, MA) using a small
pestle. Total RNA was then isolated from the tissue homogenates using a Direct-zol
RNA MicroPrep Kit (Zymo Research, Irvine, CA). The quality of the total RNA isolate
was analyzed using a Bioanalzyer RNA 6000 Nanochip (Agilent Technologies, Santa
Clara, CA) and an Agilent 2200 TapeStation (Agilent Technologies, Santa Clara, CA).
Total RNA samples deemed low quality were thrown out. From the RNA isolates,
double stranded cDNA was made via reverse transcription using a Superscript III kit
(Life Technologies, Grand Island, NY). Using this cDNA, quantitative PCR (qPCR) was
used to quantify mRNA expression of 3 genes: rgs9, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and hypoxanthine guanine phosphoribosyl transferase
(HPRT). Reactions for each sample contained 5 ng of cDNA template, SYBR Green
Master Mix (Qiagen, Valencia, CA), the primer specific to which gene was being
assayed, and molecular grade water. All samples were run in triplicate, and a standard
curve for each gene was run in duplicate. qPCR of sample reactions were performed
and analyzed using Stratagene Mx300P (Alligent Technologies, Santa Clara, CA). The
reaction protocol for SYBR green system were single incubations of 50°C for 2 minutes
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and 95°C for 15 minutes followed with 35 cycles of 95°C for 30 seconds, primer specific
annealing temperature for 30 seconds, and 72°C for one minute. A melting curve was
performed for each primer to ensure a single product was produced. Expression of rgs9
was normalized to the expression of housekeeping genes GAPDH and HPRT for each
rat. This normalization controls for loading errors and variation among samples. Fold
change in the normalized rgs9 expression was calculated compared to the normalized
rgs9 expression of F0 NS rats using the method described by Livak and Schmittgen
(Livak and Schmittgen 2001).
CREB Protein ELISA
At P60, rats from F0 NS, F0 NQ, and F1 FQxMQ treatment groups that were
behaviorally tested on PPI were decapitated and their brain tissue collected. Brains
were immediately frozen in isopentane and stored at -80°C. Nucleus accumbens tissue
was dissected from each brain and again stored at -80°C. A CREB ELISA kit was
purchased from MyBioSource (San Diego, CA, USA). The protocol provided with this kit
was closely followed. In brief, nucleus accumbens tissue was homogenized in RIPA cell
lysis buffer containing protease and phosphatase inhibitors as previously stated using a
sonic tissue homogenizer. Tissue was centrifuged, and the supernatant was collected.
CREB protein provided for use as a standard was serial diluted as described in the
protocol. The standard dilutions and samples were added to the pre-coated 96-well
plate. After incubation and wash, the provided Detection Reagent A was applied. The
plate was then incubated and washed again, and Detection Reagent B was applied.
Following another incubation and was, TMB was applied to the plate. The provided stop
solution was applied to the plate after a brief incubation. The plate was then read using
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a plate reader at a wavelength of 450 nm. Data was converted to pg/mg using the
standard curve calculated using the standard dilutions.
Statistical Analysis
All statistical analysis was performed using SPSS. In all experiments, ANOVA
was the primary statistical test performed. If an ANOVA test returned a significant group
effect, a Newman-Keuls post hoc test was performed in order to make individual
comparisons of groups within a given experiment. For all statistical comparison tests, a
p-value of less than 0.05 was used as the indicator of a statistically significance
difference between groups. Unless noted otherwise, an asterisk (*) in figures denotes a
statistically significant difference in that group compared to controls.
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CHAPTER 3
RESULTS
Transmission of Schizophrenia-like Symptoms in F1 Rats
Yawn Test
Number of yawned in a 1 hour period immediately following an acute, IP
quinpirole injection (0.1 mg/kg) for F0 NS, F0 NQ, F1 FQxMQ, F1 FQxMS, and F1
FSxMQ rats is displayed in Figure 1. Only males were administered a yawn test, due to
limits in animal availability and previous studies demonstrating that while female F0 NQ
do yawn at an increased rate compared to controls, the overall effect is less robust than
in males (Maple et al. 2015). As can be observed in Figure 1, F0 NQ rats and all three
F1 groups tested demonstrated increased yawing following an acute quinpirole
treatment compared to controls. As previously stated, yawning behavior is a dopamine
D2 receptor mediated event (Cooper et al. 1989). Therefore, these results indicate an
increase in dopamine D2 receptor sensitivity in F0 NQ animals, as well as F1 FQxMQ,
F1 FQxMS, and F1 FSxMQ animals. A one-way ANOVA revealed a significant main
effect of treatment group [F(4,43)=7.68, p<0.001]. Treatment group here and hence
forth refers to the combination of their generation number and either neonatal treatment
or parental treatment. A Newman-Keuls post hoc test indicated that while the F0 Q
group and all three F1 groups demonstrated significantly increased yawning compared
to controls (indicated by *, p<0.05), that F1 FQxMS group demonstrated significantly
decreased yawning compared to the F1 FQxMQ group (indicated by #, p<0.05).
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Figure 1. Number of times yawned for a 1-hour duration immediately following acute
quinpirole injection (0.1 mg/kg, IP) is shown as a function of treatment group in P60aged rats. F0 NQ, F1 FQxMQ, F1 FQxMS, and F1 FSxMQ all demonstrated
significantly increased yawning compared to F0 NS rats (indicated by *, p<0.05). F1
FQxMS rats demonstrated significantly less yawning compared to the F1 FQxMQ group
(indicated by #, p<0.05).

Prepulse Inhibition in Non-cross-fostered Rats
An average percent inhibition of the response to each prepulse trial decibel level
was taken for each daily session of testing in male and female rats. Values of PPI
obtained for each of the three daily sessions was averaged, to get overall PPI over
three days of testing. Additionally, startle responses to the 120 dB trials were averaged
over the 3 days of testing to determine if there were differences among the groups in
basal startle response. These results are demonstrated in Figure 2.
Male rats. As can be seen in the Figure 2a, male F0 quinpirole rats, F1 FQxMQ,
F1 FQxMS, and F1 FSxMQ animals all displayed decreased PPI over all 3 decibels of
the prepulse compared to F0 NS controls. A 3x5 two-way ANOVA confirmed these
results, with a significant main effect of treatment group [F(4,94)=16.06, p<.001] A
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Newman-Keuls post hoc test revealed that all groups demonstrated significantly
decreased PPI compared to controls. F0 NQ and all F1 groups did not differ from each
other, indicating the level of PPI deficit did not decrease across generations. Startle
response to the 120 dB trials for male rats across all three days is measured in Newtons
(N) and displayed in Figure 2b. A one-way ANOVA revealed no difference among all
treatment groups [F(4,94)=2.2, p<0.071]. Therefore, the deficit observed was the
learned association between the prepulse and the startle stimuli, and not due to an
effect alone on the startle response.
Female rats. In Figure 2c, PPI as a function of group for female rats is shown.
As can be seen, female groups demonstrated less deficits overall compared to controls.
However, a two-way repeated measures ANOVA revealed a significant effect of
treatment group [F(4,41)=6.09, p<.001] and a significant treatment group x prepulse dB
level interaction [F(8,82)=2.72, p<.01]. A Newman-Keuls post hoc test revealed that at
73 dB, F0 NQ, F1 FQxMQ, and F1 FQxMS all demonstrated significant deficits
compared to F0 NS controls and F1 FSxMQ rats (indicated by *, p<0.05). At 76 dB, F0
NQ rats demonstrated significant a significant PPI deficit compared to all other groups.
At 82 dB, there were no group differences. Figure 2d presents the startle responses to
the 120 dB trials across 3 days (measured in N) as a function of group. Here, a one-way
ANOVA did reveal a significant main effect of treatment group [F(4,44)=4.14, p<.007]. A
Newman Keuls revealed that F1 FSxMQ rats demonstrated significantly increased
startle response compared to all other groups (indicated by *, p<0.05).
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Figure 2. Average PPI and acoustic startle response in non-cross-fostered male and
female rats averaged over 3 days of testing are show. An asterisk (*) denotes significant
difference compared to F0 NS controls (p<0.05). a) Percent PPI for male non-crossfostered rats is shown. All groups demonstrated significant PPI deficits compared to
controls for all 3 dB levels. b) Acoustic startle response to 120 dB trials measured in N
for male non-cross-fostered rats is shown. No groups differed compared to F0 NS rats.
c) Percent PPI for female non-cross-fostered rats is shown. At 73 dB, F0 NQ, F1
FQxMQ, and F1 FQxMS rats differed from F0 NS controls. At 76 dB, only F0 NQ rats
differed compared to F0 NS controls. No differences were found at the 82 dB level
prepulse. d) Acoustic startle response to 120 dB trials measured in N for female noncross-fostered rats is shown. F1 FSxMQ rats demonstrated decreased startle response
compared to F0 NS controls and all other groups.
Prepulse Inhibition in Male Cross-fostered Rats
Early analysis of results of PPI in non-cross-fostered animals suggested that it
was possible maternal care of F1 animals played a role in affecting PPI performance. In
order to control for potential differences between NQ mothers of F1 rats and NS
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mothers of F1 rats, F1 rat pups were cross-fostered to mothers of the opposite neonatal
treatment group as described in the Methods and Materials section. All F0 rats were
raised by their native female dam. Additionally, due to limited number of animals that
were able to be cross-fostered, only males were included in this round of PPI testing.
Percent PPI over 3 days of testing was averaged for each dB level of prepulse in
male rats. Startle response to the 120 dB trials was also averaged over three days. All
F1 rats in this experiment were cross-fostered as described above. These results are
displayed in Figure 3. As can be seen in Figure 3a, F0 NQ, F1 FQxMQ-cf, F1 FQxMScf, and F1 FSxMQ-cf all demonstrated decreased PPI compared to F0 NS controls and
F1 FSxMS-cf rats. A 3x6 two-way ANOVA confirmed these results, with a significant
effect of treatment group [F(5,75)=17.73, p<0.001] and a significant two-way interaction
of treatment group and dB level [F(10,150)=2.01, p<0.03]. A Newman-Keuls post hoc
test revealed that all groups demonstrated significantly decreased PPI compared to
controls and F1 FSxMS-cf rats. F0 NQ, F1 FQxMQ-cf, F1 FQxMS-cf, and F1 FSxMQ-cf
rats were all equivalent.
Startle response to the 120 dB trials across all three days, measured in N, is
presented as a function of group and displayed in Figure 3b. A one-way ANOVA
revealed no difference among all treatment groups [F(4,94)=2.2, p<.071].
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Figure 3. Average PPI and acoustic startle response in cross-fostered male rats
averaged over 3 days of testing are show. An asterisk (*) denotes significant difference
compared to F0 NS controls (p<0.05). a) Percent PPI for male cross-fostered rats is
shown. All groups demonstrated significant PPI deficits compared to F0 NS controls and
F1 FSxMS-cf rats for all 3 dB levels. b) Acoustic startle response to 120 dB trials
measured in N for male cross-fostered rats is shown. No groups differed compared to
F0 NS rats.
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Transmission of Enhanced Response to Nicotine in F1 Rats
Nicotine Behavioral Sensitization
For nicotine sensitization, the unit of measure for generalized activity was
distance (m) calculated as the difference in activity from Day 1 to Day 9 of nicotine
treatment. A sensitization effect is described as an increase in a drug’s effect on a
subject after subsequent administrations of the same dose (Stewart and Badiani 1993).
Therefore, the larger the sensitization effect, the larger the difference between activity
from Day 1 to Day 9. Due to limitations in animal numbers, only female rats were
included in this experiment. Notable from previous studies, NQ treatment produced an
enhanced sensitization effect to nicotine (0.5mg/kg, IP) (Perna and Brown 2013). As
can be seen in Figure 4, animals from all tested groups administered saline (-S) at the
time of sensitization testing demonstrated no sensitization effect (Groups F0 NS-S, F0
NQ-S, F1 FQxMS-S, F1 FSxMQ-S, and F1 FQxMQ-S). F0 NS animals demonstrated
behavioral sensitization to nicotine (-N) (Group F0 NS-N), and this sensitization effect
was enhanced in the F0 NQ-N group as well as all 3 tested F1 groups administered
nicotine at the time of sensitization testing. A two-way ANOVA confirmed these results
with a significant main effect of adolescent drug treatment [F(1,45)=72.91, p,0.001]. A
Newman-Keuls post hoc test revealed that F0 NQ-N rats were statistically equivalent to
F1 FSxMQ-N, F1 FQxMS-N, and F1 FQxMQ-N rats; and these 4 groups were
significantly greater than all other groups (indicated by **, p<0.05). The post hoc test
also revealed that F0 SN rats demonstrated significantly increased sensitization
compared to F0 NS-S rats (indicated by *, p<0.05), a result which validates the nicotine
dose (0.5 mg/kg) chosen for the behavioral sensitization paradigm.
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Figure 4. Behavioral sensitization is shown as a measure of general activity (meters
moved in a locomotor arena) on day 9 minus distance moved on day 1 of the
sensitization paradigm for each treatment group, also distinguished by whether the
treatment group received nicotine (N) or saline (S) during the sensitization paradigm.
The F0 SN group demonstrated increased sensitization compared to all groups which
received saline at the time of testing (indicated by *, p<0.05). All other groups which
received nicotine at the time of testing demonstrated an enhanced sensitization effect
compared to the F0 SN group (indicated by **, p<0.05).

Nicotine Conditioned Place Preference
For CPP, the unit of measure was taken as the percent of testing time spent in
the context paired with nicotine administration on the post-conditioning test minus the
percent time spent in the paired context during the pre-conditioning test. Results are
shown in Figure 5. As can be observed, rats which received saline at the time of testing
(-S) did not show a preference for the paired context. All animals which received
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nicotine at the time of testing (-N) did show a preference for the paired context.
Compared to the control group which received nicotine (F0 NS-N), it can be observed
that the F0 NQ-N, F1 FQxMQ-N, and F1 MSxFS-N groups demonstrated enhanced
CPP to nicotine compared to F0 NS controls conditioned with nicotine. A one-way
ANOVA revealed a significant effect of treatment group [F(9,92)=14.32, p<.001]. A
Newman Keuls post hoc test confirmed that F0 NQ-N, F1 FQxMQ-N, and F1 MSxFS-N
demonstrated significantly greater CPP than all other groups (indicated by **, p<0.05),
and that F0 NQ-N and F1 FSxMQ were significantly greater than all groups conditioned
using saline but demonstrated lesser CPP than the aforementioned 3 groups (indicated
by *, p<0.05).
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Figure 5. Nicotine CPP is shown as a measure of percent of time spent in the paired
context during the post-conditioning test minus percent of time spent in the paired
context during pre-conditioning as a function of treatment group, also distinguished by
whether the treatment group received nicotine (N) or saline (S) during the sensitization
paradigm. The F0 SN group and F1 FQxMS-N group demonstrated increased
sensitization compared to all groups which received saline at the time of conditioning
(indicated by *, p<0.05). F0 QN, F1 FSxMQ-N, and F1 FQxMQ-N all demonstrated
greater CPP than all other groups (indicated by **, p<0.05).

BDNF Protein Expression Following Nicotine Sensitization
BDNF protein expression in the nucleus accumbens for females from the 5
treatment groups, given either saline or nicotine during the sensitization paradigm, is
shown in Figure 6. The brain tissue analyzed was collected 24 hours following the last
day of the sensitization paradigm. As can be observed in Figure 6, nicotine
sensitization increased BDNF expression in all groups compared to saline controls.
Additionally, F0 NQ, F1 FQxMS, F1 FSxMQ, and F1 FQxMQ groups all demonstrated
an enhanced increase in BDNF expression following nicotine sensitization compared to
F0 S animals sensitized to nicotine. A two-way ANOVA utilizing treatment group and
sensitization drug treatment as factors revealed significant effects of treatment group
[F(4,49)=2.95, p<0.03] and drug treatment [F(1,49)=32.0, p<0.001]. A Newman-Keuls
post hoc test revealed that F0 QN, F1 FQxMS-N, F1 FSxMQ-N, and F1 FQxMQ-N
groups were all significantly greater than F0 NS-S, F0 NS-N, F0 QS, F1 FQxMS-S, F1
FSxMQ-S, and F1 FQxMQ-S rats. Additionally, it was revealed that F0 NQ-S, F1
FQxMS-S, F1 FSxMQ-S, and F1 FQxMQ-S were all significantly increased compared to
controls (F0 NS-S). In total, it appears that NQ treatment produces increases in BDNF
protein expression which are transmitted by either parent to the F1 generation. BDNF
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was also increased in animals sensitized to nicotine, and this effect was enhanced by
NQ treatment, and also observed in the F1 generation.

Figure 6. BDNF protein expression in the nucleus accumbens is shown as a function of
treatment group, also distinguished by whether the group received nicotine (N) or saline
(S) during sensitization paradigm. The F0 SN, F0 QS group, and all three F1 groups
which received saline during sensitization paradigm demonstrated increased BDNF
expression 24 hours after the final sensitization injection (indicated by *, p<0.05). F0
QN, and all three F1 groups which received nicotine during sensitization paradigm
demonstrated an enhanced increase in BNDF expression compared to all other groups
(indicated by **, p<0.05).
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Suggested Mechanisms for Epigenetically Transmitted Effects
Rgs9 mRNA Expression
mRNA levels for rgs9 were assayed in the nucleus accumbens using qPCR as
previously described for F0 NS, F0 NQ, and F1 FQxMQ animals. As can be seen in
Figure 7, no difference was demonstrated between the 3 assayed groups. A one-way
ANOVA confirmed this observation [F(2,17)=1.706, p=0.2112]. Due to lack of
significance in primary groups in which variation in rgs9 mRNA expression was
hypothesized and supported by a previous study (Maple et al. 2007), additional
treatment groups were not assayed.

Figure 7. Percent of the control group (F0 NS) of rgs9 mRNA expression in the nucleus
accumbens is shown as a function of treatment group. Though a slight increase in mean
percent control is evident in the F1 FQxMQ, no statistically significant differences were
detected among the 3 assayed groups.
Rgs9 mRNA Expression Following Nicotine Treatment
mRNA levels for rgs9 were again assayed in the nucleus accumbens using
qPCR as previously described. In total, 5 groups were assayed: F0 NS-S, F0 NS-N, F1
FQxMQ-N, F1 FSxMQ-N, F1 FQxMS-N. In this analysis of rgs9 mRNA, animals in all
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treatment groups, except for a subset of F0 S animals, received 6 days of once daily
nicotine injections (0.5 mg/kg, IP) starting on P54, and brain tissue was collected 24
hours following the final injection. Results in Figure 8 are shown as a percentage
difference compared to control animals (F0 S). A one-way ANOVA revealed a
significant effect of treatment group [F(4,21)=4.85, p<0.009]. A Newman-Keuls post hoc
test revealed that F1 FQxMQ-N demonstrated significantly increased rgs9 mRNA.

Figure 8. Percent of the control group (F0 NS-S) of rgs9 mRNA expression in the
nucleus accumbens is shown as a function of treatment group. Every group except the
control group received 6 days of daily nicotine injections (0.5 mg/kg, IP) prior to tissue
collection. F1 FQxMQ-N demonstrated increased rgs9 mRNA expression (indicated by
*, p<0.05).
CREB Protein Expression
CREB protein expression in the nucleus accumbens was assayed using an
ELISA kit as previously described. Three treatment groups were assayed including F0
NS, F0 NQ, and F1 FQxMQ rats. Tissue for this analysis was taken at P60. As can be
seen in Figure 9, both F0 NQ and F1 FQxMQ groups were increased compared to F0
NS rats, which serve as controls. A one-way ANOVA confirmed this observation, finding
a significant effect of treatment group on CREB expression [F(1,26)=15.87, p<0.001]. A
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Newman Keuls post hoc test revealed that F0 NQ and F1 FQxMQ animals were
equivalent and significantly increased compared to F0 NS animals (p<0.05).

Figure 9. CREB protein expression in the nucleus accumbens is shown as a function of
treatment group. F0 NQ and F1 FQxMQ groups are significantly increased compared to
controls (F0 NS) (indicated by *, p<0.05).

51

CHAPTER 4
DISCUSSION
This study represents the first example of a transgenerational model of
schizophrenia. Though many models utilize epigenetic mechanisms to confer
schizophrenia-like symptoms in rodents (i.e. poly IC rodent model and MAM rodent
model), none have examined epigenetic transmission of schizophrenia-like symptoms
from parental rodents to their offspring. Several effects related to schizophrenia were
demonstrated to have been transmitted to the F1 generation of the NQ rodent model.
These effects can largely be explained by hypersensitivity in dopamine D2 receptor
signaling, an effect which has been thoroughly studied in the NQ rodent model (Maple
et al. 2007; Maple et al. 2015; Kostrzewa et al. 2016).Behavioral and neurobiological
results obtained during this project suggest that dopamine D2 receptor hypersensitivity
is transmitted at least one generation past the point of NQ treatment, and this effect
appears to occur independent of which parental sex was neonatally treated with
quinpirole.
Evidence of Epigenetic Transmission of Schizophrenia-like Symptoms
Dopamine D2 Receptor Hypersensitivity in F1 Rats
Results from the yawn test, displayed in Figure 1, indicate that dopamine D2
receptor sensitivity is transmitted to the F1 generation when at least one parent is
treated neonatally with quinpirole. Though the yawn test relies on secondary, behavioral
effects conferred by quinpirole treatment, agonist/antagonist treatment targeting the
dopamine D2 receptor has indicated that yawning behavior is directly tied to receptor
sensitivity (Cooper et al. 1989; Kostrzewa and Brus 1991; Collins et al. 2005).
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Elevated yawning in F0 NQ rats compared to F0 NS rats replicates previous
findings that NQ treatment produces increased yawing behavior following acute
quinpirole treatment at P60, and thus demonstrates increases of dopamine D2 receptor
sensitivity (Maple et al. 2007). Increases in yawning behavior in F1 FQxMQ, F1 FQxMS,
and FSxMQ all indicate that either parent rat of F1 groups can confer increased
dopamine D2 receptor sensitivity to offspring. However, it appears that female F0 NQ
rats may contribute less to this effect, indicated by a lesser increase in yawning in F1
FQxMS rats. This effect is somewhat surprising, as there are many more avenues for
maternal epigenetic contribution compared to relatively few paternal epigenetic
contributions. Paternal contribution is largely limited to the contents of the sperm
genome and epigenome. Even these contributions are diminished, as it appears that
partial demethylation of paternal DNA may occurs upon zygote formation, an effect
which does not appear to affect maternal genetic contribution (Oswald et al. 2000). In
contrast, maternal epigenetic contribution occurs not only directly through gamete DNA,
but also maternal uterus conditions, placental environment, and delivery timing
(Wilhelm-Benartzi et al. 2012; Dhobale et al. 2013; Salilew-Wondim et al. 2014; Banik et
al. 2017). Maternal care also plays a role in pup development, as differences in
maternal care may lead to long-term epigenetic manipulations (Champagne 2008;
McGowan et al. 2011; Bagot et al. 2012). Therefore, MQ animals appearing to
contribute more to dopamine D2 receptor hypersensitization is a noteworthy finding.
The finding that male contribution alone leads to increased dopamine D2 receptor
sensitivity indicated the robustness of the dopamine-linked effects conferred by NQ
treatment. Increased yawning across all F1 groups in Figure 1 indicates the utility of the
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NQ model in studying the epigenetic transmission of dopamine D2 receptor sensitivity,
and its relation to schizophrenia due to the NQ model’s many consistencies with the
disorder.
Prepulse Inhibition Deficits in F1 Rats.
Male PPI. PPI results shown in Figure 2a and Figure 3a indicate that
sensorimotor gaiting deficits are transmitted from F0 NQ rats to male F1 rats with at
least one parent treated neonatally with quinpirole. Preliminary data collected during this
project initially suggested there to be differences among F1 rats, which could have
potentially been explained by a maternal care effect. This was due to early analysis with
low sample sizes suggesting that the F1 FSxMQ did not demonstrate PPI deficits.
Therefore, in order to control for a potential maternal care effect, future testing of PPI
included a subset of F1 animals which were cross-fostered to a maternal rat of the
opposite treatment group (Figure 3a). However, as rats were added to the study, mean
percent PPI decreased in the F1 FSxMQ group, and that group demonstrated
equivalent PPI deficits to F0 NQ and other F1 groups. Therefore, results for the noncross-fostered and cross-fostered subsets did not differ relative to F0 NQ and F0 NS
controls. Additionally, an F1 FSxMS cross-fostered group was added to the crossfostered subset, to investigate if maternal care performed by a neonatal quinpiroletreated female would alter PPI performance in what are essentially wild-type rats. As
can be observed in Figure 3a, the F1 FSxMS-cf group performed at similar levels to F0
NS control rats, indicating that maternal care by a rat treated neonatally with quinpirole
does not alter performance on PPI in isolation. Therefore, when discussing PPI results,
it is not necessary to differentiate between cross-fostered and non-cross-fostered
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animals. Additionally for this reason, cross-fostering was not considered as a factor in
analysis of experiments in this study except for PPI.
Male startle response. Startle response data was also collected during each
PPI session and analyzed using Newtons (N) exerted by the rat on the weight-sensing
plate as the measure. Startle response has been characterized as a motor reflex to a
startle-inducing stimulus, and is thought to be achieved through a relatively noncomplex, short pathway involving brain stem input and motor neurons (Koch and
Schnitzler 1997). Altered startle response to stimuli such as the 120 dB pulse trials
described above would affect PPI results, as PPI for each animal is calculated as a
percent of the startle response. However, as indicated in Figure 2b for male non-crossfostered rats and Figure 3b for cross-fostered rats, no significant difference in startle
response was demonstrated across all male F0 or F1 groups.
Female PPI and startle response. PPI in female rats produced less robust
deficits across treatment groups and dB level of prepulse (Figure 2c and 2d). Deficits in
F0 NQ female rats were only present at 73 dB and 76 dB trials, and deficits in F1 rats
were only present at 73 dB (F1 FQxMQ and F1 FQxMS). Additionally, female F1
FSxMQ rats demonstrated reduced startle response to 120 dB pulse trials compared to
all other groups. This effect was not seen in either non-cross-fostered or cross-fostered
males. These results are not entirely surprising, as sex differences have been reported
in rodent PPI (Lacy et al. 2011). These sex differences could in part be explained by
estrous cycle in females (Koch 1998), but the present study did not further investigate
potential causes of these sex differences. It is because of the lack of robust results in
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females that only males were examined in the cross-fostered subset of PPI testing. This
decision was made due to limited access to cross-fostered animals.
PPI remains one of the most translationally relevant behavioral tests with
respects to schizophrenia and other neurological disorders which include sensorimotor
gaiting deficits as a symptom. PPI has also been tied to dopamine dysregulation.
Therefore, PPI deficits in F1 rats with at least one quinpirole parent serves as further
indication that dopamine dysregulation caused by NQ treatment is transgenerational.
PPI deficits in humans and schizophrenia models have been shown to be alleviated by
antipsychotic treatment (Kumari and Sharma 2002). Thus, PPI may serve as a
screening tool for the investigation of additional treatment options as well. Further
investigation of PPI performance utilizing novel intervention strategies in this
transgenerational model of schizophrenia could lead to a better understanding of
schizophrenia etiology as well as novel treatment options.
Evidence of Epigenetic Transmission of Enhanced Response to Nicotine
Enhanced Behavioral Sensitization and CPP to Nicotine in F1 Rats
Behavioral sensitization to nicotine. Behavioral sensitization to stimulants is
an increase in response to repeated drug treatments utilizing equivalent doses.
Behavioral sensitization paradigms such as the one previously described and utilized in
this study are thought to model the development of addiction (Pierce and Kalivas 1997).
Therefore, in a model of schizophrenia such as the NQ model, one would expect to see
increases in this effect, as nicotine addiction is much more prevalent in people
diagnosed with schizophrenia (Salokangas et al. 2006; Featherstone and Siegel 2015).
Increased nicotine sensitization effect in F0 NQ rats has been demonstrated in multiple
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studies (Perna and Brown 2013; Peterson et al. 2017). This effect appears to be in part
due to an increase in accumbal BDNF, and are attenuated by antagonization of α4β2
nicotinic receptors, indicating a critical role for this receptor in mediating sensitization to
nicotine (Peterson et al. 2017).
Nicotine conditioned place preference. CPP to nicotine has previously been
shown to be enhanced in NQ rats (Perna et al. 2011). While robust CPP to nicotine has
been shown to not present in adult rats (Clarke and Fibiger 1987), CPP to nicotine has
been demonstrated in adolescent rats (Belluzzi et al. 2004). Adolescent age points are
of particular importance to schizophrenia, as this is when symptoms of the disorder
typically tend to manifest (Owen et al. 2016), as well as when cigarette smoking often
initiates (DiFranza et al. 2000). The findings in Figure 5 replicate past results that F0
NQ rats demonstrate an enhanced CPP effect to nicotine (0.6 mg/kg, IP) compared to
F0 NS controls, and also demonstrate that this effect is transmitted epigenetically to F1
FQxMQ and F1 FSxMQ adolescent rats. These findings indicate that paternal
epigenetic contribution from rats with increased dopamine D2 receptor sensitivity spawn
F1 rats which are susceptible to experience enhanced associative effects to nicotine.
This suggests that paternal dopamine D2 receptor sensitivity epigenetically contributes
to drug abuse vulnerability in nicotine.
The present study indicates that susceptibility to enhanced nicotine sensitization
present in F0 NQ animals is an effect which is transmitted to F1 rats with at least one
parent treated neonatally with quinpirole (Figure 4 and Figure 5). While F0 NS rats did
show a significant sensitization and CPP to nicotine, these effects were further
enhanced by NQ treatment, as well as in the F1 generation rats with at least one
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quinpirole treated parent. The only exception to this finding was that in nicotine CPP, F1
FQxMS-N rats did not demonstrate an enhanced response compared to F0 NS-N rats.
Therefore, it appears that male NQ parents contribute more strongly to the transmission
of enhanced behavioral response to nicotine. This finding is slightly surprising, as
females are often thought to contribute more strongly to the inheritance of epigenetic
effects (Guo et al. 2014; Tang et al. 2015).
Previous studies have demonstrated multiple potential mechanisms in F0 NQ
rats. F0 NQ rats sensitized to nicotine demonstrate increased dopamine release in the
nucleus accumbens as well as enhanced neurotrophic factor response to nicotine
(Brown et al. 2012; Perna and Brown 2013). This effect in concert with increased
dopamine D2 receptor sensitivity has great implications on the reward system in the
brain of these rodents.
Increased Accumbal BDNF in F1 Rats Following Nicotine Sensitization
Increased BDNF protein expression following nicotine sensitization is an effect
which has been previously shown in the NQ rodent model (Peterson et al. 2017). This
study investigated whether this effect was transmitted to F1 rats of the quinpirole model
as well, as increased BDNF protein expression in the nucleus accumbens, an area
critical in mediating drug addiction, could at least in part explain the enhanced nicotine
sensitization effect demonstrated by both F0 NQ rats and F1 rats with at least one
parent treated neonatally with quinpirole. BDNF is a protein which has been implicated
in both schizophrenia as well as addiction, and is well documented in the literature of
both of these disorders (Vargas-Perez et al. 2009; Nieto et al. 2013; Chen et al. 2015; Li
and Wolf 2015; Gören 2016; Bobadilla et al. 2019; Marinho et al. 2019). Results of this
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study indicate that the effect of enhanced BDNF expression following nicotine
sensitization previously described in F0 NQ rats is also present in F1 rats with at least
one parent treated neonatally with quinpirole (Figure 6). Once again, it does not appear
that which parental sex received NQ treatment in order to confer the potential of
increased accumbal BDNF following nicotine sensitization, further indicating the strong,
long-lasting effect NQ has on the epigenome. BDNF’s role in maintaining plasticity at
synaptic connections (Lu et al. 2015; Kowiański et al. 2018) may explain its role in
mediating increased sensitization, and thus addiction, given its increased expression in
the nucleus accumbens of rats which demonstrate enhanced response to nicotine.
Neurobiological Mechanisms Involved in Epigenetic Transmission to F1 Rats
Accumbal rgs9 mRNA Expression
Previous study of rgs9 in the NQ model indicated a decrease in accumbal and
striatal rgs9 mRNA measured utilizing in situ hybridization (Maple et al. 2007). This
effect at least in part would explain increased dopamine D2 receptor sensitivity, since as
previously mentioned, rgs9 binding to dopamine D2 receptors decreases their affinity for
dopamine (Cabrera-Vera et al. 2004). However, as can be seen in Figure 7, accumbal
mRNA levels of rgs9 via qPCR did not differ among F0 NS controls and F0 NQ or F1
FQxMQ rats. The reason for discrepancy from previous studies to this could be
explained by differences in assay methods, but exact reason for this discrepancy is
unclear. It is also recognized that mRNA levels may not directly correspond with protein
levels, and future studies continuing the investigation of epigenetic mechanisms in the
NQ model will further investigate rgs9.
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Effect of nicotine on rgs9 expression. Rgs9 mRNA was also assayed via
qPCR in animals which received 6 once-daily injections of nicotine (0.5mg/kg, IP).
Results are shown in Figure 8. F1 FQxMQ-N rats were the only group demonstrated
significantly altered rgs9 mRNA expression, as this group was increased. To our
knowledge, this is the first time rgs9 has been investigated in a rodent model in
conjunction with nicotine administration. Increase in F1 FQxMQ-N rats following nicotine
administration suggests alternations to dopamine signaling, potentially as a
compensatory measure for dopamine hyperactivity in the nucleus accumbens following
nicotine administration, as dopamine increases in the nucleus accumbens have been
reported in F0 NQ rats following nicotine administration (Perna and Brown 2013). Given
F1 FQxMQ rats’ consistencies with F0 NQ rats, it would make sense that this effect may
also be present in F1 generation animals. However, the exact mechanism for the
increase in rgs9 expression following nicotine administration is unclear, and why this
effect is not seen in additional groups is also unknown.
Accumbal CREB Expression
Though CREB is expressed throughout the brain, alterations in its expression in
the nucleus accumbens have been linked to symptoms consistent with schizophrenia
including PPI deficits (Culm et al. 2004) and blunted emotional response to aversive
stimuli (Carlezon et al. 2005). In addition, increases in CREB activity have been linked
to increased dopamine D2 receptor activation (Yan et al. 1999). Here, we demonstrate
that accumbal CREB is increased in both F0 NQ rats as well as F1 FQxMQ rats
compared to control animals (Figure 9). However, there are no clinical data showing
changes of CREB in the nucleus accumbens in the post-mortem brain tissue of
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individuals diagnosed with schizophrenia. The roles of CREB in the pathology of
schizophrenia have been discussed in a recent paper by Wang and colleagues. Studies
have shown that dopamine, antipsychotic drugs, growth factors, and other
schizophrenia-related genes could activate CREB and its downstream target BDNF via
different pathways (Wang et al. 2018). Alterations of CREB/BDNF signaling have been
found in schizophrenia, but the precise characterization of these mechanisms are not
currently clear. Preclinically, it has been shown that chronic quinpirole to adult rats
produces an improvement in PPI and decreases of CREB in the nucleus accumbens
(Culm et al. 2004). This may appear to contradict our results. However, chronic
quinpirole treatment to adult rats is known to produce a decrease of dopamine D2
receptor density, and result in downregulation of dopamine D2 receptors (Subramaniam
et al. 1992). Since NQ treatment results in an increase of dopamine D2 receptor
sensitivity, but not change in receptor number, it is possible that CREB is positively
correlated with changes in dopamine D2 receptor signaling, with increases in D2
signaling resulting in an increase of accumbal CREB, and a decrease in D2 signaling
associated with decreased accumbal CREB. While this conclusion is speculative, the
data appear to support this explanation as a possibility. Although this result does not
necessarily mechanistically explain dopamine D2 receptor hypersensitivity seen in F0 or
F1 rats of the NQ model, it does at least in part explain downstream behavioral effects
such as sensorimotor gaiting deficits seen in previous studies in F0 rats (Maple et al.
2015) and in this study in F0 and F1 rats.
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Limitations
Proving transgenerational epigenetic transmission poses many challenges. For
example, it is possible that quinpirole exerts off-target environmental impact such as
cytotoxicity on germline cells that results in altered phenotype in the F1 generation,
which is not the same mechanism of increased dopamine D2 receptor sensitivity
demonstrated in F0 NQ rats. In order to rule out environmental impact of quinpirole or
other environmental stimuli on germline and other supporting cells in the neonatally
treated breeder rats, at least one generation succeeding F1 animals must be studied.
Investigation of an F2 generation and succeeding generations is especially important
when lacking evidence of specific epigenetic mechanisms demonstrated to be present
in germline cells (Horsthemke 2018).
Though this study details a case for the existence of epigenetic mechanisms of
transmission of schizophrenia-like effects in the NQ rodent model, a thorough
investigation into those mechanisms was not performed. Factors contributing to this
deficiency include both resources and a lack of a robust understanding of mechanisms
contributing to dopamine D2 receptor hypersensitivity in the F1 generation of the NQ
model. The behavioral establishment of this model was the priority of this particular
study, and a complete investigation into the mechanisms underlying these effects is an
immense task. Regardless, investigation into specific epigenetic mechanisms in
germline cells, and behavioral testing of an F2 generation of animals could rule out
mechanisms of non-epigenetic transmission of the behavioral and neurobiological
phenotype demonstrated in this study.
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Additionally, due to restrictions of time and rat availability, sample sizes were not
large enough in many of the performed experiments to be able to analyze potential sex
differences with sufficient statistical power. Sex differences have previously been
detailed in the NQ rodent model (Perna and Brown 2013; Maple et al. 2015; Peterson et
al. 2017) and human schizophrenia (Mendrek and Mancini-Marïe 2016; Gonçalves et al.
2019). Therefore, analysis of sex differences with regards to epigenetic transmission of
schizophrenia-like phenotype in the NQ model could lead to improvements in current
schizophrenia diagnosis and treatment. Future continuation of this line of research will
serve to allow these analyses.
Conclusions
Overall, this study provides evidence of epigenetic transmission of
schizophrenia-like effects in the NQ rodent model of schizophrenia. These findings
provide evidence of epigenetic transmission of dopamine D2 receptor hypersensitivity,
which builds upon the relatively small knowledge of the epigenetic impact of
schizophrenia-like conditions. For instance, data presented in Figure 1 indicates that
dopamine D2 receptor hypersensitivity in a parent is transmitted to offspring, even if
only one parent is afflicted. Though this effect likely presents more strongly in rodents
than it would in the human population due to the much smaller level of variability and
other confounding factors exhibited in lab rodents, its examination in isolation
demonstrates that alterations in dopamine signaling have potential to be robustly
transmitted epigenetically. Transmission of sensorimotor gaiting deficits to F1 rats with
at least one F0 NQ parent demonstrates that neurobiological alterations caused by drug
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treatment, or potentially neurological environment in neurological disorders, can be
epigenetically transmitted to mediate behavioral phenotype as well.
This study also provides evidence that drug abuse vulnerability is caused by
dopamine D2 receptor hypersensitivity, and this effect is epigenetically transmitted to F1
rats. Increased sensitization and CPP to nicotine indicate NQ rats model drug abuse
vulnerability, an effect which could partially be attributed to increases in neurotrophic
factors such as BDNF following nicotine administration. Further studies into
mechanisms of epigenetic transmission which allow for enhanced response to nicotine
to manifest across multiple generations of the NQ model would help to better
understand risk factors of drug abuse, allowing for preventative or earlier intervention in
individuals vulnerable to drug abuse development. Given the high level of abuse of
nicotine among individuals diagnosed with schizophrenia, understanding the epigenetic
link between dopamine D2 receptor hypersensitivity and nicotine abuse would also help
to fill knowledge-gaps about the etiology of schizophrenia, other behavioral disorders
that present with psychosis, and their high rate of comorbidity with nicotine abuse. Due
to the high rate of treatment resistance in schizophrenia (Taylor and Duncan-McConnell
2000), and many individuals likely relying on nicotine to relieve negative symptoms
associated with schizophrenia (LeDuc and Mittleman 1995), better understand of the
largely unknown epigenetic components of the link between schizophrenia and nicotine
abuse could lead to novel treatment options.
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